A Phase I Study of OSI-906 in Combination With Pemetrexed in Advanced Solid Tumor Malignancies
Status:
Withdrawn
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to test the safety of an experimental drug called OSI-906 when
combined with pemetrexed at different dose levels and to find out the optimal doses of the
two drugs that can be given as a combination. Pemetrexed has been widely used for treatment
of certain solid organ tumors and is effective and approved for use in treatment of lung
cancer and mesothelioma.